3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Neoplasms
4
Prostatic Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Substance-Related Disorders
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Interventions
Rituximab
52
Cyclophosphamide
42
fludarabine phosphate
41
Peripheral Blood Stem Cell Transplantation
41
Whole-Body Irradiation
26
Mycophenolic Acid
25
Cyclosporine
21
Bortezomib
21
Dexamethasone
19
Busulfan
18
Tacrolimus
17
Etoposide
17
Filgrastim
15
Antilymphocyte Serum
14
Methotrexate
13
Melphalan
13
ibrutinib
12
Radiotherapy
11
Calcium Dobesilate
9
Sirolimus
8
Lenalidomide
8
Cyclosporins
8
Methylprednisolone
7
Flow Cytometry
7
Everolimus
7
Carboplatin
7
ibritumomab tiuxetan
6
zanubrutinib
5
fludarabine
5
Transplantation
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Waldenstrom Macroglobulinemia
×
Patient Reported Outcome Measures
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled